Compositions and methods for the treatment of cellulite
Described herein are methods and formulations for treating, inhibiting, or ameliorating cellulite. Aspects described herein relate to formulations including a saline solution, reactive oxygen species, a rheology agent, an emollient, and a pH modifier and methods of using these formulations for treating, ameliorating, or inhibiting cellulite.
1 . A cellulite treatment formulation, comprising:
an electrolyzed saline solution comprising a salt, wherein the salt is Himalayan sea salt;
a reactive oxygen species comprising hypochlorite;
a rheology agent;
an emollient, wherein the emollient is dimethicone, cyclomethicone, or a blend thereof; and
a pH modifier,
wherein the formulation has an osmolality measurement ranging from about 3 to about 5 mOsm/kg.
2 . The cellulite treatment formulation of claim 1 , wherein the salt is present in an amount of about 0.01% to about 1% w/v.
3 . The cellulite treatment formulation of claim 1 , wherein the salt is present in an amount of about 0.05% w/v.
4 . The cellulite treatment formulation of claim 1 , wherein the salt is raw, unprocessed salt.
5 . The cellulite treatment formulation of claim 1 , wherein the hypochlorite is present in an amount of about 25 to about 100 ppm.
6 . The cellulite treatment formulation of claim 1 , wherein the hypochlorite is present in an amount of about 72 ppm.
7 . The cellulite treatment formulation of claim 1 , wherein the rheology agent is a metal silicate.
8 . The cellulite treatment formulation of claim 1 , wherein the rheology agent is sodium magnesium silicate present in an amount of about 0.5% to about 10% w/v.
9 . The cellulite treatment formulation of claim 1 , wherein the emollient is present in an amount of about 0.5% to about 10% w/v.
10 . The cellulite treatment formulation of claim 1 , wherein the pH modifier is sodium phosphate monobasic present in an amount of about 0.05% to about 5% w/v.
11 . The cellulite treatment formulation of claim 1 , wherein the formulation is in the form of a cream, foam, gel, serum, lotion, mousse, ointment, paste, solution, spray, stick, or suspension.
12 . The cellulite treatment formulation of claim 1 , wherein the formulation comprises:
salt in an amount of about 0.01% to about 1% w/v;
hypochlorite in an amount of about 60 to about 80 ppm;
sodium magnesium silicate in an amount of about 0.5% to about 10% w/v;
dimethicone in an amount of about 0.5% to about 10% w/v; and
sodium phosphate monobasic in an amount of about 0.05% to about 5% w/v.
13 . The cellulite treatment formulation of claim 1 , wherein the salt comprises:
aluminum in an amount ranging from 32 to 241 ppm;
calcium in an amount ranging from 1290 to 2101 ppm;
iron in an amount ranging from 23 to 141 ppm;
magnesium in an amount ranging from 217 to 1944 ppm; and
potassium in an amount ranging from 149 to 1174 ppm.
14 . The cellulite treatment formulation of claim 1 , wherein the pH of the formulation ranges from about 6.5 to about 7.0.
15 . A method of reducing an appearance of cellulite in a subject in need thereof, the method comprising:
identifying a region of a body having cellulite; and
topically applying to the region of the body a cellulite treatment formulation comprising:
an electrolyzed saline solution comprising raw salt, wherein the raw salt is Himalayan sea salt;
hypochlorite;
a rheology agent;
an emollient, wherein the emollient is dimethicone, cyclomethicone, or a blend thereof; and
a pH modifier;
wherein the formulation has an osmolality measurement ranging from about 3 to about 5 mOsm/kg, thereby reducing the appearance of cellulite.
16 . The method of claim 15 , wherein the hypochlorite is present in an amount of 0.0025 to 0.01% w/v in the formulation.
17 . The method of claim 15 , further comprising massaging the formulation into the region of the body having cellulite until absorbed.
18 . The method of claim 15 , wherein the formulation is administered daily to the region of the body having cellulite.
19 . The method of claim 15 , wherein reducing the appearance of cellulite comprises increasing skin elasticity, reducing subcutaneous fat nodularity, or increasing lipolysis in adipocytes.
20 . The method of claim 15 , wherein the raw salt is present in an amount of about 0.01% to about 1% w/v.
21 . The method of claim 15 , wherein the raw salt is present in an amount of about 0.05% w/v.
22 . The method of claim 15 , wherein the hypochlorite is present in an amount of about 25 to about 100 ppm.
23 . The method of claim 15 , wherein the hypochlorite is present in an amount of about 72 ppm.
24 . The method of claim 15 , wherein the rheology agent is a metal silicate.
25 . The method of claim 15 , wherein the rheology agent is sodium magnesium silicate present in an amount of about 0.5% to about 10% w/v.
26 . The method of claim 15 , wherein the emollient is present in an amount of about 0.5% to about 10% w/v.
27 . The method of claim 15 , wherein the pH modifier is sodium phosphate monobasic present in an amount of about 0.05% to about 5% w/v.
28 . The method of claim 15 , wherein the formulation is in the form of a cream, foam, gel, serum, lotion, mousse, ointment, paste, solution, spray, stick, or suspension.
29 . The method of claim 15 , wherein the formulation comprises:
raw salt in an amount of about 0.01% to about 1% w/v;
hypochlorite in an amount of about 60 to about 80 ppm;
sodium magnesium silicate in an amount of about 0.5% to about 10% w/v;
dimethicone in an amount of about 0.5% to about 10% w/v; and
sodium phosphate monobasic in an amount of about 0.05% to about 5% w/v.
30 . The method of claim 15 , wherein the raw salt comprises:
aluminum in an amount ranging from 32 to 241 ppm;
calcium in an amount ranging from 1290 to 2101 ppm;
iron in an amount ranging from 23 to 141 ppm;
magnesium in an amount ranging from 217 to 1944 ppm; and
potassium in an amount ranging from 149 to 1174 ppm.
31 . The method of claim 15 , wherein the pH of the formulation ranges from about 6.5 to about 7.0.